Assessing the Utility of Genetic Tests

Genetic testing is a rapidly expanding area with many clinical applications. While the introduction of new genetic tests creates tremendous potential for improving patient care, it is essential to adequately evaluate these tests to ensure their accuracy and utility for clinical practice. This article describes a general approach to the evaluation of genetic tests and discusses common challenges that evaluators face. This article's goal was to provide a starting point for those who are concerned with the safety and utility of genetic tests to develop an overall strategy to perform the assessment.

[1]  P. De Bievre,et al.  The revised international vocabulary of basic and general terms in metrology (VIM) , 2006 .

[2]  N. Aronson,et al.  HER2 testing to manage patients with breast cancer or other solid tumors. , 2008, Evidence report/technology assessment.

[3]  J. Yerushalmy.  Statistical problems in assessing methods of medical diagnosis, with special reference to X-ray techniques. , 1947, Public health reports.

[4]  J. Loop,et al.  American College of Radiology Diagnostic Efficacy Studies. , 1978, AJR. American journal of roentgenology.

[5]  F. O'Malley,et al.  Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer , 2007, Current oncology.

[6]  T. Trikalinos,et al.  Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. , 2007, Evidence report/technology assessment.

[7]  Ralf Schulze,et al.  The efficacy of diagnostic imaging. , 2012, Dento maxillo facial radiology.

[8]  C. Gatsonis.  Design of evaluations of imaging technologies: development of a paradigm. , 2000, Academic radiology.

[9]  David B Matchar,et al.  Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). , 2007, Evidence report/technology assessment.

[10]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[11]  K. Hudson,et al.  Public Health at Risk: Failures in Oversight of Genetic Testing Laboratories , 2006 .

[12]  Bin Chen,et al.  Good laboratory practices for molecular genetic testing for heritable diseases and conditions. , 2009 .

[13]  G H Guyatt,et al.  A framework for clinical evaluation of diagnostic technologies. , 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  Muin J Khoury,et al.  What is the clinical utility of genetic testing? , 2006, Genetics in Medicine.

[15]  Linda A Bradley,et al.  Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review , 2009, Genetics in Medicine.

[16]  W. Bruening,et al.  Quality, Regulation and Clinical Utility of Laboratory-developed Molecular Tests , 2010 .

[17]  C. Mulrow,et al.  Current methods of the US Preventive Services Task Force: a review of the process. , 2001, American journal of preventive medicine.

[18]  GAO-06-977T Nutrigenetic Testing: Tests Purchased from Four Web Sites Mislead Consumers , 2006 .

[19]  S. Teutsch,et al.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.

[20]  Eileen Erinoff,et al.  Addressing Challenges in Genetic Test Evaluation: Evaluation Frameworks and Assessment of Analytic Validity , 2011 .

[21]  Alejandro J Necochea,et al.  Outcomes of genetic testing in adults with a history of venous thromboembolism. , 2009, Evidence report/technology assessment.

[22]  A. Berchuck,et al.  Genomic tests for ovarian cancer detection and management. , 2006, Evidence report/technology assessment.